Titan Medical shareholders approve 30-1 reverse split

June 15, 2018 By Brad Perriello Leave a Comment

Titan Medical (TSX:TMD;OTC:TITFX) shareholders this week approved a reverse stock split that could see the company exchange a single share for as many as 30.

The robot-assisted surgery company, which lists its shares on the OTC exchange in the U.S. and on the Toronto Stock Exchange, said earlier this month that the reverse split is slated to go into effect June 19 when the markets open. Titan also wants to move its U.S. listing to the NASDAQ exchange; the reverse split is aimed at meeting the exchange’s listing requirements.

Today Titan said some 88.1% of the more than 297 million shares voted at the meeting approved the split at a to-be-determined ratio of a common share for as few as five or as many as 30 outstanding shares.

“We believe that dual-listing our common stock on both the TSX and NASDAQ presents the opportunity to expand awareness of the company among U.S.-based investors and potentially provides avenues for additional sources of funding as we work to complete the development of the Sport surgical system,” president & CEO David McNally said when the split was announced earlier in June. “The considerable progress we have made in product development, strengthening our intellectual property portfolio, the successful demonstration of the first simulation training modules with our collaborator Mimic Technologies, and most recently, surgeons presenting abstracts at renowned medical conferences, all underlie the timing of this decision. The consolidation of our shares is a necessary step to meet NASDAQ’s listing requirements and we anticipate that our stock will be listed by the end of June.”

Titan said the reverse split is expected to take the number of outstanding shares from about 420 million to roughly 14 million at the one-for-30 ratio.

TITFX shares were up 1.0% to 20.38¢ apiece today in early trading in New York; TMD shares were flat at C26.5¢ in Toronto.

Inside Hologic's evolving definition of women's healthcare

Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.

At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!

REGISTER NOW

Use code WOMENSHEALTH to save an additional 10%.

Medtech should think deeper about the problems its trying to solve
Medtech can improve by thinking more about the problems it is trying to solve and looking outside of normal avenues for inspiration. Jeff Karp, Brigham and Women’s Hospital, Harvard Medical School. For companies and academics aiming to innovate in the medical space, we often don’t spend enough time thinking about the problem we are trying… […]
5 tips for post-market medical device compliance
Post-market surveillance is an important process for medical device developers and an expectation of regulatory bodies that you follow through and have effective procedures. Jon Speer, Greenlight Guru In fact, post-market surveillance is a compliance issue that many companies get caught up with in audits or inspections. So how comfortable is your medtech company with the… […]
11 pediatric cardiovascular devices you need to know
A bandage-sized heart monitor, an extracorporeal blood pump that mimics the human heart, and a heart valve that can grow with a child were among the six winners of a contest yesterday in Philadelphia for innovative pediatric cardiovascular devices. The Pediatric Device Innovation Symposium organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at… […]
Meddux Development receives ISO 13485:2016 certification
Meddux Development announced that it has received ISO 13485:2016 certification for its quality management system. “The certification to ISO 13485:2016 allows Meddux to offer its customers a streamlined path from concept to first-in-human clinical trials, David Schechter, president of Meddux, said. “Meddux has developed a flexible and responsive QMS capable of handling the most critical… […]
6 questions to ask when designing polymer components for medical devices
Choosing the right polymer for the job can be a daunting task. Here are the right questions to ask before you begin the process. Karen Heroldt, PolyOne Distribution Choosing polymers is complicated in the high-stakes world of medical and healthcare devices. Materials can have varied tool design, molding and secondary processing requirements that can affect… […]
Medtech M&A remains hot: Here’s how
M&A in medtech show no signs of slowing in the fourth quarter of 2018, and companies looking to buy or sell have much to consider, according to patent attorney David Dykeman, a shareholder in the Boston office of the global law firm Greenberg Traurig. The number of medtech M&A deals soared by 50% in 2017 and… […]
Olympus touts line of needles for GI disease improvement
Olympus is touting its new EZ Shot 3 Plus 25 G needles that is designed to help improve the staging of GI disease. The 25 G needle is an addition to the EZ Shot 3 Plus 19 G and 22 G needles that Olympus already markets. Olympus’s new EZ Shot 3 Plus 25 G needles… […]
Mindray North America picks Eastman medical polymers for patient monitors
Mindray is using Eastman’s medical polymers in its present generation of patient monitors in order to improve chemical resistance to cleaning/disinfection agents and increase device longevity, the companies recently announced. Thanks to the Eastman polymers, Mindray’s Passport series of bedside monitors, T1 monitor/module and Accutorr series of spot check monitors are now fully compatible with more than… […]
Cincinnati Children’s researchers report progress growing a human esophagus in a lab
It’s possible to use pluripotent stem cells to grow human esophageal organoids — another step toward the goal of someday bioengineering the entire esophagus and human gastrointestinal system in a lab, according to researchers at Cincinnati Children’s Center for Stem Cell and Organoid Medicine (CuSTOM). The Cincinnati Children’s researchers describe the advance as a first. Pluripotent stem… […]
How strong patent portfolios attract strategic investments and deals
Amassing strong patent portfolios helps medical device companies attract interest from strategic investors and potential acquirers. David J. Dykeman, Greenberg Traurig and Patrick West, Mirus Capital Advisors The medical device industry has demonstrated strong and sustainable growth in recent years. Given the aging population, increasing incidence of chronic and lifestyle diseases, emergence of artificial intelligence (AI)… […]
NucleusHealth wins investment from large Ohio health system
Cloud-based medical image exchange company NucleusHealth has landed an undisclosed “strategic investment” from Mercy Health, an Ohio–based health care system that is now a minority investor in the San Diego, Calif.-based company. NucleusHealth will use the money to help deliver Nucleus.io, the first cloud-based Picture Archiving Communications System (PACS) platform designed to use the security, scalability and… […]